Saxenda® (liraglutide) injection 3 mg becomes the first FDA-approved therapy to treat obesity in adolescents in more than a decade PLAINSBORO, N.J., Dec. 4, 2020 /PRNewswire/ -- Novo Nordisk today ...

In the ever-evolving symphony of weight loss medications, Saxenda (Liraglutide) has long taken center stage as a virtuoso in pharmaceutical solutions for shedding unwanted pounds. Yet, the search for ...

The weight-loss drug liraglutide helped obese children lower their BMI and reach a healthier weight, researchers report. The findings, published Tuesday in the New England Journal of Medicine and ...

Saxenda (liraglutide) is a GLP-1 agonist injection pen medication used to support long-term weight loss in adults with obesity, adults with overweight and weight-related health issues, and certain ...

As the demand for affordable healthcare options grows, the pharmaceutical industry is increasingly focused on developing generic drugs to expand access and reduce costs. This trend is driving major ...

Share on Pinterest Experts say people should expect to be on weight loss medications for a long period of time. NurPhoto/Getty Images Researchers report that more than half of people on weight loss ...

World Health Organization advisors will meet next month to decide whether liraglutide will be added to the organization’s updated Essential Medicines List, making the drug available in all hospital ...

The FDA has approved Saxenda® (liraglutide; Novo Nordisk) as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in patients aged 12 years and older with ...

INDIANAPOLIS — Eli Lilly's stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound. CVS Health said the drugs Wegovy and Saxenda from rival ...

Novo Nordisk A/S (NVO) announced that the FDA has approved an updated label for Saxenda (liraglutide) injection 3 mg. The Saxenda Injection is now approved for the treatment of obesity in adolescents ...

A new FDA-approved product with the potential to triple weight loss in obesity patients should be a huge win for the company. Those efforts may pay off very soon for patients and investors alike. A ...